Doctors and many patients say GLP-1 drugs can help solve the growing problem of obesity. But some bristle at the thought that ...

Novo Nordisk said on Friday the U.S. Food and Drug Administration had granted accelerated approval for its weight-loss drug Wegovy to treat a serious liver condition known as metabolic ...

The move follows a Trump administration push to reduce drug prices in America (or, at least, effectively level them across the world). In late July, the president sent letters to the CEOs of top U.S.

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...

Eli Lilly plans to increase prices of medicines in Europe and other developed markets “in order to make them lower” in the ...

US pharma major Eli Lilly is raising the list price for its obesity drug Mounjaro (tirzepatide) in the UK by as much as 170%, as the pharma industry comes under pressure from US President Donald Trump ...

Mounjaro's UK price will rise by 170% in September, prompting interest in cheaper alternatives like semaglutide for weight loss.

By Dennis Thompson HealthDay ReporterFRIDAY, Aug. 15, 2025 (HealthDay News) — “Forever” PFAS chemicals might hamper a teenager’s ability to drop excess weight, even if they’ve undergone weight-loss ...

By Brooke Hudspeth, Pharm.D. University of Kentucky You’ve likely heard about glucagon-like peptide-1 agonists – usually ...

Superluminal will use its AI-driven platform to discover and optimize small-molecule treatments for G protein-coupled receptors, or GPCRs, which have emerged as a key to conditions such as diabetes ...

An Anthem Blue Cross subscriber is suing the health insurer, alleging she was wrongfully denied coverage for Zepbound for weight management because she was no longer considered morbidly obese. Alicia ...